Bioray Biotech Co., Ltd
Bioray Biotech Co., Ltd engages in the production, research, and sells health foods, immune cell products, and precision testing services in Taiwan. It offers health care products, including various functional foods and supplements; medicinal fungi; immune cell products; and precision medicine services, such as immunology, cell division, and specialized laboratory testing. The company is also inv… Read more
Bioray Biotech Co., Ltd (7561) - Total Liabilities
Latest total liabilities as of June 2025: NT$84.01 Million TWD
Based on the latest financial reports, Bioray Biotech Co., Ltd (7561) has total liabilities worth NT$84.01 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bioray Biotech Co., Ltd - Total Liabilities Trend (2019–2024)
This chart illustrates how Bioray Biotech Co., Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bioray Biotech Co., Ltd Competitors by Total Liabilities
The table below lists competitors of Bioray Biotech Co., Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EnBio Co. Ltd.
KQ:352940
|
Korea | ₩25.93 Billion |
|
AIM Commercial Growth Freehold And Leasehold Real Estate Investment Trust
BK:AIMCG
|
Thailand | ฿498.60 Million |
|
Mason Capital Corporation
KQ:021880
|
Korea | ₩13.70 Billion |
|
Veranda Resort Public Company Limited
BK:VRANDA
|
Thailand | ฿3.91 Billion |
|
PNC Technologies co. Ltd
KQ:237750
|
Korea | ₩21.30 Billion |
|
CRTUF
PINK:CRTUF
|
USA | $12.88 Million |
|
Advance Metals Ltd
AU:AVM
|
Australia | AU$379.29K |
|
Profoto Holding AB
ST:PRFO
|
Sweden | Skr453.00 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Bioray Biotech Co., Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bioray Biotech Co., Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bioray Biotech Co., Ltd (2019–2024)
The table below shows the annual total liabilities of Bioray Biotech Co., Ltd from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$122.90 Million | +13.01% |
| 2023-12-31 | NT$108.75 Million | -26.10% |
| 2022-12-31 | NT$147.16 Million | +43.91% |
| 2021-12-31 | NT$102.25 Million | -1.73% |
| 2020-12-31 | NT$104.05 Million | +189087.27% |
| 2019-12-31 | NT$55.00K | -- |